<DOC>
	<DOCNO>NCT00778388</DOCNO>
	<brief_summary>The objective confirm optimal dose IC43 regard immunogenicity , safety tolerability .</brief_summary>
	<brief_title>Study Assessing Safety Immunogenicity IC43 Vaccination Against Pseudomonas Aeruginosa Healthy Volunteers</brief_title>
	<detailed_description>The study design multi‐center , observer‐blinded , randomize , placebocontrolled phase 1 study healthy adult subject 18 65 year age . A total 160 healthy male female subject plan enrol randomized five group receive different dosage formulation IC43 placebo .</detailed_description>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>write informed consent obtain prior study entry healthy adult age 18 65 year clinically relevant pathological finding investigation Screening visit . Minor deviation laboratory value normal range may accept , judge investigator clinical relevance In female subject either childbearing potential terminate surgery negative serum pregnancy test screen willingness become pregnant entire study period practice reliable method contraception History autoimmune disease malignancy Active passive vaccination 4 week entire study protocol Use investigational nonregistered drug vaccine addition study vaccine study period within 30 day precede first dose study vaccine History severe hypersensitivity reaction anaphylaxis Known hypersensitivity allergic reaction one component vaccine Clinically significant disease judge investigator Immunodeficiency due immunosuppressive therapy A family history congenital hereditary immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Pseudomonas Aeruginosa</keyword>
</DOC>